| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 4255 | 2018 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1973 | 2020 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1583 | 2018 |
| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1481 | 2017 |
| The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy V Gopalakrishnan, BA Helmink, CN Spencer, A Reuben, JA Wargo Cancer cell 33 (4), 570-580, 2018 | 1252 | 2018 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... Cancer discovery 6 (8), 827-837, 2016 | 980 | 2016 |
| Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ... Science translational medicine 9 (379), eaah3560, 2017 | 800 | 2017 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ... Nature medicine 24 (11), 1649-1654, 2018 | 768 | 2018 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 511 | 2021 |
| Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ... Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019 | 319 | 2019 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 298 | 2021 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The Lancet Oncology 19 (2), 181-193, 2018 | 290 | 2018 |
| Identification of bacteria-derived HLA-bound peptides in melanoma S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ... Nature 592 (7852), 138-143, 2021 | 289 | 2021 |
| Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases GM Fischer, A Jalali, DA Kircher, WC Lee, JL McQuade, LE Haydu, ... Cancer discovery 9 (5), 628-645, 2019 | 289 | 2019 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 176 (1), 404, 2019 | 228 | 2019 |
| Immuno-genomic landscape of osteosarcoma CC Wu, HC Beird, J Andrew Livingston, S Advani, A Mitra, S Cao, ... Nature communications 11 (1), 1008, 2020 | 199 | 2020 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 194 | 2020 |
| Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy JA Wargo, A Reuben, ZA Cooper, KS Oh, RJ Sullivan Seminars in oncology 42 (4), 601-616, 2015 | 192 | 2015 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 191 | 2017 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 183 | 2021 |
